钟茜

• 基本情况

中山大学肿瘤防治中心检验科教授、博士后合作导师、医学技术专业博士生导师，广东省“特支计划”科技创新青年拔尖人才，目前担任中国研究型医院学会病毒肿瘤学专委会副主委、中国抗癌协会肿瘤标志专业委员会青委会委员、广东省抗癌协会肿瘤分子诊断专委会常委等。先后主持国家科技重大专项慢病2030项目课题、科技部“863青年科学家”课题，4项国自然面上项目；作为合作方负责人承担了国自然区域联合重点项目。近五年以最后通讯/共同通讯发表的主要代表作发表在Nature、Cell Res、Lancet Digit Health、Cell Death & Differ、Nat Commun、Cell Rep Med、MED、J Extracell Vesicles、Adv Sci、Genome Med等。

• 主持科研项目
  1. 癌症、心脑血管、呼吸和代谢性疾病防治研究、国家科技重大专项课题《EB病毒疫苗研发》课题负责人--项目《鼻咽癌风险分层策略、早诊和疫苗研发》课题四 （2023ZD0501004）216万，2024.7-2028.6
  2. 863青年科学家项目: 鼻咽癌靶向多肽在分子影像和靶向治疗中的应用(2015AA020931)（2015.01-2017.12）126万，已结题
  3. 国家自然科学基金委面上项目: 识别EBV糖蛋白中和表位抗体的筛选及其在诊断中的应用 (82572641)（2026.01-2029.12）49万
  4. 国家自然科学基金委面上项目: 基于超级增强子驱动的核心调控网络在鼻咽癌中的作用及机制研究 (82072982)（2021.01-2024.12）55万，已结题
  5. 国家自然科学基金委面上项目: ZIC2在鼻咽癌中对EB病毒感染的调控作用及机制研究(81772883)（2018.01-2021.12）55万，已结题
  6. 国家自然科学基金委面上项目: ZIC2作为乳腺癌候选抑癌基因的作用及机制(81572600)（2016.01-2019.12）62万，已结题
• 发表文章
  1. Li Y^#, Zhang H^#, Sun C^#, Dong XD^#, …, McGuire AT, Zhao B, Bei JX, Robertson E, Zeng YX, Zhong Q*, Zeng MS* R9AP is a common receptor for EBV infection in epithelial cells and B cells. Nature 2025 Aug;644(8075):205-213. doi: 10.1038/s41586-025-09166-w.
  2. Wang Y^#, Xing S^#,…, Cao SM*, Liu WL*, Zeng MS*, Zhong Q^*. An extracellular vesicle protein-based machine learning framework for early detection of oesophageal squamous cell carcinoma: a multicentre, prospective study. Journal of Extracellular Vesicles 2026, Mar;15(3):e70246. doi: 10.1002/jev2.70246.
  3. Hu ZL^#, Li ZQ^#, Wang Y^#, Luo YL, Guo WP, Meng N, Bu GL, Zhang LL, Li SX, Kong XW, Fang XY, Wang QL, Han RK, Zhao Z, Zhao GX, Jiang ZY, Jin RX, Zeng MS*, Zhong Q*. Extracellular vesicles derived EBV tegument protein BRRF2 suppresses cGAS phase separation to promote anti-viral innate immune evasion. Nature Communication 2025 Oct 10;16(1):9015. doi: 10.1038/s41467-025-64037-2.
  4. Yang T^#, Lin ZR^#, Xia TL^#,…,Zeng MS*, Zhong Q^*. The PLEKHA1-TACC2 fusion gene drives tumorigenesis via vascular mimicry formation in esophageal squamous-cell carcinoma. Cell Death & Differentiation, 2025 Jul 5. doi: 10.1038/s41418-025-01536-1.
  5. Liu SX^#, Wu TW^#,…,Zeng MS*, Zhong Q^*. Interferon-responsive HEVs drive tumor tertiary lymphoid structure formation and predict immunotherapy response in nasopharyngeal carcinoma. Cell Reports Medicine, 2025 Jun 17;(0):102200 DOI:10.1016/j.xcrm.2025.102200
  6. Lin ZR^#, Xia TL^#,…,Zeng MS*, Zhong Q^*. Inactivation of TACC2 epigenetically represses CDKN1A and confers sensitivity to CDK inhibitors. Med, 2025 Jan 5:100568.  doi: 10.1016/j.medj.2024.12.002.
  7. Li SB^#, Yuan L^#, Zhu QY^#, Zhang G^#, Liu YT, Gao MH, Han F, Lin ZR, Zhang H, Tang LQ, Sun L, He QY, Song EW, Young LS, Li YC, Mai HQ, Zeng MS^*, Zhong Q^*. OASL enhances mRNA translation and reprograms lipid metabolism to promote cancer progression. Cell Reorts 2025 Jul 2;44(7):115901. doi: 10.1016/j.celrep.2025.115901
  8. Wang Y^#, Xing S^#,…, Zhong Q^*, Liu WL^*, Zeng MS^*. Highly sensitive detection platform-based diagnosis of oesophageal squamous cell carcinoma: a multicentre, case-control, diagnostic study. Lancet Digital Health, 2024, Oct;6(10):e705-e717.
  9. Wan XD^#, Liu YT^#, Peng YM^#, Wang J^#, Yan SM^#, Zhang L, …, Liu Y^*, Zeng MS^*, Chen C^*, Zhong Q^*. Primary and orthotopic murine models of nasopharyngeal carcinoma reveal molecular mechanisms underlying its malignant progression, Advanced Science, 2024 Sep;11(36):e2403161. 
  10. Sun C^#, Kang YF^#, Fang XY^#, Liu YN^#, Bu GL, Wang AJ, Li Y, Zhu QY, Zhang H, Xie C, Kong XW, Peng YJ, Lin WJ, Zhou L, Chen XC, Lu ZZ, Xu HQ, HONG DC, Zhang X, Zhong L, Feng GK, Zeng YX, Xu M, Zhong Q^*, Liu Z^*, Zeng MS^*. A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV. Cell Host & Microbe. 2023 Oct 6:S1931-3128(23)00378-5
  11. Dai DL^#, Xie C^#, Zhong LY^#, Liu SX, Zhang LL, Zhang H, Wu XP, Wu ZM, Kang K, Li Y, Sun YM, Xia TL, Zhang CS, Zhang A, Shi M, Sun C, Chen ML, Zhao GX, Bu GL, Liu YT, Huang KY, Zhao Z, Li SX, Zhang XY, Yuan YF, Wen SJ, Zhang L, Li BK*, Zhong Q*, Zeng MS*. AXIN1 boosts antiviral response through IRF3 stabilization and induced phase separation. Signal Transduction and Targeted Therapy 2024 Oct 9;9(1):281. doi: 10.1038/s41392-024-01978-y.
  12. Zhao GX^#, Bu GL^#, Liu GF^#, Kong XW, Sun C, Li ZQ, Dai DL, Sun HX, Kang YF, Feng GK^*, Zhong Q^*, Zeng MS^* mRNA-based Vaccines Targeting the T-cell Epitope-rich Domain of Epstein Barr Virus Latent Proteins Elicit Robust Anti-Tumor Immunity in Mice. Advanced Science. 2023. Oct 27:e2302116.
  13. Liu SX^#, Wang C^#, Lin RB^#, Ding WY^#, Roy G, Wang HB, Yang T, Liu Q, Luo YL, Zeng MS^*, Zhao Bo^*, Zhong Q^* Super-enhancer driven SOX2 promotes tumor formation by chromatin re-organization in nasopharyngeal carcinoma. eBiomedicine, 2023 Dec:98:104870. doi: 10.1016/j.ebiom.2023.104870. Epub 2023 Nov 14.
  14. Li JP, Wu CY, Chen MY, Liu SX, Yan SM, Kang YF, Sun C, Grandis JR, Zeng MS* Zhong Q*. A PD-1+CXCR5-CD4+ Th-CXCL13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma. Journal for ImmunoTherapy of Cancer (JITC), 2021 Jul;9(7):e002101. doi: 10.1136/jitc-2020-002101.
  15. Chen ZH^#, Yan SM^#, Chen XX^#, Zhang Q^#, Liu SX^#, Liu Y, Luo YL, Zhang C, Xu M, Zhao YF, Huang LY, Liu BL, Xia TL, Xu DZ, Liang Y, Chen YM, Wang W, Yuan SQ, Zhang HZ, Yun JP, Zhai WW, Zeng MS^*, Bai F^*, Zhong Q^*. The genomic architecture of EBV and infected gastric tissue from precursor lesions to carcinoma. Genome Medicine 2021 Sep 7;13(1):146. doi: 10.1186/s13073-021-00963-2.
  16. Jin S^#, Li R^#, Chen MY^#, Yu C^#, Tang LQ^#, Liu YM, Li JP, Liu YN, Luo YL, Zhao Y, Zhang Y, Xia TL, Liu SX, Liu Q, Wang GN, You R, Peng JY, Li J, Han F, Wang J, Chen QY, Zhang L, Mai HQ, Gewurz BE, Zhao B, Young LS, Zhong Q*, Bai F*, Zeng MS*. Single-cell transcriptomic analysis defines the interplay between tumor cells, viral infection, and the microenvironment in nasopharyngeal carcinoma. Cell Research 2020 Nov;30(11):950-965. doi: 10.1038/s41422-020-00402-8.